Loading…
Ensysce Biosciences, Inc. is projected to rise to $0.3099 by 2027, a +11% move from its current price of $0.2801. ENSC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.2709 | $0.2801 | $0.2896 | +0.01% |
| Aug 6 | $0.2673 | $0.2801 | $0.2936 | +0.01% |
| Aug 7 | $0.2645 | $0.2801 | $0.2968 | +0.02% |
| Aug 8 | $0.2621 | $0.2802 | $0.2994 | +0.02% |
| Aug 9 | $0.2601 | $0.2802 | $0.3018 | +0.03% |
| Aug 10 | $0.2583 | $0.2802 | $0.304 | +0.03% |
| Aug 11 | $0.2566 | $0.2802 | $0.306 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2566 | $0.2802 | $0.306 | +0.04% |
| Week 2 | $0.2475 | $0.2803 | $0.3175 | +0.07% |
| Week 3 | $0.2407 | $0.2804 | $0.3266 | +0.11% |
| Week 4 | $0.2352 | $0.2805 | $0.3345 | +0.14% |
| Week 5 | $0.2305 | $0.2806 | $0.3416 | +0.18% |
| Week 6 | $0.2262 | $0.2807 | $0.3482 | +0.21% |
| Week 7 | $0.2224 | $0.2808 | $0.3544 | +0.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on prescription drugs for severe pain relief related to opioid misuse, abuse, and overdose in the United States.
The company develops products using the Trypsin Activated Abuse Protection (TAAP) platform and the Multi-Pill Abuse Resistance (MPAR) platform. Its lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; PF614-MPAR is a combination product of PF614 and nafamostat for overdose protection.
Ensysce was founded in 2003 and is based in La Jolla, California. It is also developing PF8001 and PF8026 as extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder.
Ensysce Biosciences, Inc. trades at a current price of $0.251 with a market cap of $3.86M and a rank of 5104. The stock is positioned in the lower end of the market by market capitalization and price level.
The forecast shows a varied price path, with a 2026 average of $0.251 and a 2026 max of $0.3392. The outlook evolves toward higher targets into the longer term, with a 2040 average of $0.4947 and a 2050 average of $0.6354, and a max forecast of $0.9304 in 2040 and $1.33 in 2050. These figures imply long-run upside potential, but are treated as estimates rather than guarantees.
By 2050, the forecast max price is $1.33, with a long-run average near $0.6354 and a cumulative implied upside reflected in a 153.1% ROI. The nearer years show a mix of neutral to bullish sentiment, underscoring a higher potential but with substantial uncertainty.
A major floor 22.3% below — a decisive break under it would weaken the trend.
The nearest floor, 10.4% below — buyers have tended to step in here.
The nearest ceiling, 7.8% above — a clean break opens room to run.
A major ceiling 117.8% above — clearing it would confirm fresh momentum.
Key ENSC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENSC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.2552 | Buy | $0.2569 | Buy |
| MA 10 | $0.265 | Buy | $0.2628 | Buy |
| MA 20 | $0.2732 | Buy | $0.27 | Buy |
| MA 50 | $0.2783 | Buy | $0.2994 | Sell |
| MA 100 | $0.3676 | Sell | $0.431 | Sell |
| MA 200 | $0.8213 | Sell | $1.26 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.11 | Neutral |
| Stoch RSI (14) | 11.54 | Buy |
| CCI (20) | -123.98 | Sell |
| Williams %R (14) | -95.24 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -13.06 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 4.76 | Buy |
| TRIX (15) | -0.28 | Sell |
| Awesome (5,34) | -0.02 | Sell |
| Ultimate (7,14,28) | 26.84 | Buy |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.25 | Buy |
| ADX (14) | 12.83 | Neutral |
| ATR (14) | 0.01 | Info |
The 30-day technical picture is bearish, with RSI(14) at 40.
The price is $0.251, which sits at the stated support level of $0.251 and below the SMA50 of $0.2819. The SMA200 stands at $0.8739, indicating the stock remains well below the longer-term average.
The 30-day range spans from $0.1964 to $0.3208, highlighting a relatively wide, volatile swing for a small-cap name.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.251 | $0.2801 | $0.3733 | 0% | Neutral | |
| $0.2424 | $0.3099 | $0.4219 | +11% | Neutral | |
| $0.2574 | $0.341 | $0.4854 | +22% | Bullish | |
| $0.22 | $0.3001 | $0.4422 | +7% | Neutral | |
| $0.1976 | $0.2767 | $0.4194 | -1% | Neutral | |
| $0.2159 | $0.3095 | $0.4811 | +10% | Neutral | |
| $0.2222 | $0.3257 | $0.5177 | +16% | Neutral | |
| $0.2557 | $0.3828 | $0.6208 | +37% | Bullish | |
| $0.2657 | $0.4057 | $0.6701 | +45% | Bullish | |
| $0.2466 | $0.3838 | $0.6449 | +37% | Bullish | |
| $0.3191 | $0.5424 | $0.9785 | +94% | Bullish | |
| $0.3638 | $0.7226 | $1.44 | +158% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.251 | $0.2801 | $0.3416 | +0.00% |
| September 2026 | $0.2315 | $0.2754 | $0.3381 | -1.67% |
| October 2026 | $0.2345 | $0.2814 | $0.3499 | +2.16% |
| November 2026 | $0.2438 | $0.2945 | $0.3701 | +4.68% |
| December 2026 | $0.242 | $0.2943 | $0.3733 | -0.09% |
Click any year to see its month-by-month ENSC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Ensysce Biosciences, Inc.'s 2026 outlook centres on $0.2801, within a $0.251 to $0.3733 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ENSC could reach as high as $0.4219, with a base case around $0.3099 and support toward $0.2424 — roughly +11% from $0.2801. A consolidation phase looks the most probable path here.
Expect ENSC to range from $0.2574 to $0.4854 through 2028. The $0.341 average target implies a +22% move from current prices. That is up +10% on the projected 2027 average. Momentum favours further upside here.
The ENSC price prediction for 2029 points to an average of $0.3001 (low $0.22, high $0.4422) — a potential gain of +7% on today's $0.2801. A consolidation phase looks the most probable path here.
In 2030, ENSC is projected to trade between $0.1976 and $0.4194, averaging $0.2767 — a potential decline of -1% from today's $0.2801. That is -8% versus the projected 2029 average. Price action looks broadly range-bound.
Ensysce Biosciences, Inc.'s 2031 outlook centres on $0.3095, within a $0.2159 to $0.4811 range. That is up +12% on the projected 2030 average. That marks a +10% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, ENSC could reach as high as $0.5177, with a base case around $0.3257 and support toward $0.2222 — roughly +16% from $0.2801. Price action looks broadly range-bound.
Expect ENSC to range from $0.2557 to $0.6208 through 2033. The $0.3828 average target implies a +37% move from current prices. That is up +18% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ENSC price prediction for 2034 points to an average of $0.4057 (low $0.2657, high $0.6701) — a potential gain of +45% on today's $0.2801. Momentum favours further upside here.
In 2035, ENSC is projected to trade between $0.2466 and $0.6449, averaging $0.3838 — a potential gain of +37% from today's $0.2801. That is -5% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
Ensysce Biosciences, Inc.'s 2040 outlook centres on $0.5424, within a $0.3191 to $0.9785 range. That is up +41% on the projected 2035 average. That marks a +94% change versus current levels. Momentum favours further upside here.
By 2050, ENSC could reach as high as $1.44, with a base case around $0.7226 and support toward $0.3638 — roughly +158% from $0.2801. Buyers look set to stay in control over this stretch.
Investing $1,000 in ENSC today (≈ 3,570.153517 ENSC) could be worth
$2,579.96
+$1,579.96 (+158%) by 2050 · US Dollar
Based on the average projected ENSC price of $0.72 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENSCwould be worth at today's price.
$1,000 invested in ENSC on Jul 31, 2025 (≈ 478.468919 ENSC) would be worth
$134.02
-$865.98 (-86.6%) today · 0.13× · US Dollar
Based on a ENSC entry price of $2.09 vs. today's $0.2801.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.261 | $1,073.18 | +7.3% |
| 1 month ago | $0.302 | $927.48 | -7.3% |
| 3 months ago | $0.389 | $720.05 | -28.0% |
| 6 months ago | $0.71 | $394.51 | -60.5% |
| 1 year ago | $2.09 | $134.02 | -86.6% |
| All time (5.0y) ago | $16,380 | $0.02 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENSC forecast.
Our base-case forecast reaches $0.56 around 2050.
Implied market cap at $0.56: $8.6M
The multi-year forecast shows a progression from near-term neutral to more bullish outcomes in the longer horizon.
In 2026 the average is $0.251 with a max of $0.3392 and ROI of 0%, reflecting neutral sentiment at the outset.
From 2027 through 2029 the forecast exhibits growth potential: 2027 avg $0.2824 with ROI 12.5%, 2028 avg $0.3109 with ROI 23.9%, and 2029 avg $0.2659 with ROI 5.9%.
In 2030 the forecast turns modestly negative with an avg of $0.2453, max $0.3825, and ROI -2.3%, followed by 2031 avg $0.2783 (ROI 10.9%) and 2032 avg $0.2895 (ROI 15.3%).
From 2033 onward the outlook turns more bullish: 2033 avg $0.3482 (max $0.584, ROI 38.7%), 2034 avg $0.3704 (max $0.6337, ROI 47.6%), and 2035 avg $0.3424 (max $0.5967, ROI 36.4%).
The bullish trend strengthens into 2040 with an average of $0.4947, a max of $0.9304, and ROI of 97.1%; and by 2050, the average reaches $0.6354 with a max of $1.33 and ROI of 153.1%. These figures represent estimates, not guarantees, and reflect uncertainty in longer-horizon outcomes.
Tap a question to reveal the answer.
Avg $0.2453, min $0.1706, max $0.3825; ROI -2.3%; sentiment Neutral.
The forecast shows mixed signals across years, with 2026 Neutral and 0% ROI, and later years showing bullish potential (e.g., max $1.33 by 2050 and ROI 153.1%). These are estimates and not guarantees.
The forecast maximum by 2050 is $1.33, indicating it could reach or exceed $1 by 2050 according to the provided numbers.
Current price $0.251; Market cap $3.86M.
Avg $0.4947; max $0.9304; ROI 97.1%; sentiment Bullish.
Ensysce Biosciences, Inc. Community Discussion
0Share your Ensysce Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.